Advancing Microbiome Frontiers: A Deep Dive into Anaerobutyricum soehngenii
In the rapidly evolving landscape of Live Biotherapeutic Products (LBPs), the gut microbiome has transitioned from a mysterious ecosystem to a goldmine of therapeutic potential. Among the myriad of bacterial species populating the human intestine, Anaerobutyricum soehngenii (formerly known as Eubacterium hallii) has emerged as a cornerstone of metabolic health. As a leading Contract Research Organization (CRO) dedicated to the preclinical advancement of LBPs, Creative Biolabs recognizes that the journey from microbial discovery to clinical validation is fraught with complexity. This profile serves as a comprehensive gateway into the world of A. soehngenii, detailing its biological significance, its burgeoning role in disease treatment, and the specialized preclinical services we offer to accelerate your research from the benchtop to the clinic.
Overview of Anaerobutyricum soehngenii
Anaerobutyricum soehngenii is a Gram-positive, anaerobic bacterium belonging to the Lachnospiraceae family. It is a common inhabitant of the healthy adult gut microbiome, typically accounting for a significant portion of the total bacterial community. What sets this strain apart is its sophisticated metabolic versatility. It is a key member of the "butyrate-producing" guild, playing a vital role in the anaerobic breakdown of complex carbohydrates and the subsequent production of short-chain fatty acids (SCFAs). Unlike many other butyrate producers that rely solely on primary fermentation, A. soehngenii is a metabolic "cross-feeder." It can utilize intermediates like lactate and acetate, often produced by other beneficial microbes like Bifidobacterium, and convert them into butyrate. This ability to stabilize the gut environment by consuming potentially acidifying metabolites makes it an essential architect of intestinal homeostasis.
Beyond its role in SCFA production, A. soehngenii is involved in bile acid metabolism. It possesses enzymes that contribute to the deconjugation and conversion of primary bile acids into secondary bile acids. This function is critical because bile acids act as signaling molecules that regulate glucose metabolism, lipid profiles, and systemic inflammation via receptors like TGR5 and FXR.
Specialized Preclinical Research Services
Navigating the preclinical phase of LBP development requires a blend of microbiology, immunology, and pharmacology. Our CRO provides a vertically integrated suite of services specifically tailored for A. soehngenii research.
We provide deep-dive phenotypic and genotypic analysis. This includes Whole Genome Sequencing (WGS) to identify antibiotic resistance genes, virulence factors, and metabolic pathways. We also perform growth optimization studies to determine the ideal fermentation conditions (pH, temperature, and carbon sources) for high-titer production.
Before moving to animal models, we utilize advanced in vitro systems to validate the strain's efficacy. Our "Gut-on-a-Chip" models and intestinal epithelial cell lines (such as Caco-2 or HT29) allow us to measure the strain's ability to strengthen tight junctions, produce SCFAs in a simulated environment, and modulate immune responses in co-culture with human immune cells.
Understanding the "survival and transit" of a live microbe is essential. We utilize quantitative PCR (qPCR) and 16S rRNA sequencing to track the colonization dynamics, persistence, and localization of A. soehngenii within the gastrointestinal tract following oral administration.
Product Solutions for Preclinical Research
To support your internal R&D efforts, we offer a range of high-quality products specifically designed for the study of Anaerobutyricum species.
Research-Grade Bacterial Concentrates
We provide standardized, lyophilized (freeze-dried) powders of A. soehngenii with guaranteed viability and purity. These are available in various concentrations (CFU/g) to suit different dosing requirements in animal studies.
Anaerobutyricum soehngenii L2-7 is an anaerobe, mesophilic, Gram-positive bacterium that forms circular colonies and was isolated from Infant, faecal sample.
The therapeutic interest in A. soehngenii is primarily driven by its profound impact on host metabolism and gut barrier integrity. Current research is focusing on several key therapeutic areas where this strain acts as a potent Live Biotherapeutic.
Type 2 Diabetes and Insulin Resistance
One of the most promising applications for A. soehngenii is in the treatment of metabolic syndrome and Type 2 Diabetes. Clinical and preclinical studies have shown that the administration of this strain can significantly improve insulin sensitivity. The mechanism is multifaceted: by increasing butyrate levels, A. soehngenii stimulates the secretion of glucagon-like peptide-1 (GLP-1) from intestinal L-cells. This hormone enhances insulin secretion and slows gastric emptying. Furthermore, the modulation of bile acids by the strain helps improve systemic glucose handling.
Obesity and Nonalcoholic Fatty Liver Disease (NAFLD)
Research suggests that A. soehngenii may help mitigate the effects of high-fat diets. By reinforcing the intestinal barrier, often referred to as "closing the gut", it prevents the translocation of lipopolysaccharides (LPS) into the bloodstream. This reduction in metabolic endotoxemia prevents the low-grade chronic inflammation that drives adipose tissue dysfunction and hepatic steatosis (fatty liver).
Inflammatory Bowel Disease (IBD)
Butyrate is the primary energy source for colonocytes. In conditions like Ulcerative Colitis and Crohn's disease, butyrate levels are often depleted. A. soehngenii acts as a continuous "butyrate factory" within the gut, promoting mucosal healing, reducing oxidative stress, and downregulating pro-inflammatory cytokines such as TNF-alpha and IL-6.
Cardiovascular Health
The strain's involvement in bile acid signaling and cholesterol metabolism positions it as a candidate for cardiovascular risk reduction. By altering the circulating bile acid pool, A. soehngenii can influence lipid absorption and the inflammatory state of the vascular endothelium.
Our Competitive Advantages
Choosing the right partner for your live biotherapeutic research is critical. Here is why our CRO stands out in the field of Anaerobutyricum studies.
Deep Anaerobic Expertise
Unlike general CROs, we specialize in strict anaerobes. Our laboratories are equipped with state-of-the-art anaerobic chambers and fermentation suites designed to handle sensitive microbes that cannot tolerate even trace amounts of oxygen.
Regulatory Insight
We don't just provide data; we provide data that meets the rigorous standards for Investigational New Drug (IND) applications. Our protocols are designed with future clinical trials in mind, ensuring a seamless transition from preclinical to clinical phases.
Customized Study Design
We recognize that every drug development program is unique. Our team of PhD-level microbiologists and metabolic experts works closely with you to design bespoke studies that address your specific therapeutic targets and mechanisms of action.
Integrated Omics Platforms
We combine traditional microbiology with cutting-edge transcriptomics, metabolomics, and metagenomics. This "multi-omics" approach provides a holistic view of how A. soehngenii alters the host environment, offering deeper insights into its safety and efficacy.
Bridging the Gap Between Microbe and Medicine
The potential of Anaerobutyricum soehngenii to revolutionize the treatment of metabolic and inflammatory diseases is immense. However, the path to a successful therapeutic requires rigorous validation, precise characterization, and a deep understanding of the delicate interplay between the microbe and the human host.
As your dedicated CRO partner, Creative Biolabs is committed to providing the technical excellence and scientific rigor necessary to unlock the full potential of this remarkable bacterium. By combining our specialized preclinical services with our high-quality research products, we empower you to move forward with confidence. Let us help you transform the promise of A. soehngenii into a life-changing reality for patients worldwide. Together, we can shape the future of microbiome-based medicine.
Is Anaerobutyricum soehngenii the same as Eubacterium hallii?
Yes, the species was recently reclassified. While much of the historical literature refers to it as Eubacterium hallii, the correct taxonomic name is now Anaerobutyricum soehngenii. Our research services account for all known strains within this reclassified genus.
Can you help with the formulation of the live strain?
Absolutely. We offer formulation development services, including encapsulation technologies designed to protect the live bacteria from gastric acid, ensuring delivery to the small intestine and colon.
What is the typical lead time for a preclinical efficacy study?
Lead times vary depending on the model (e.g., a chronic DIO model takes longer than an acute colitis model), but generally, a comprehensive study can be completed within 12 to 20 weeks, including final data analysis and reporting.
Do you offer safety and toxicity testing?
Yes, we provide compliant safety assessments, including acute and sub-chronic toxicity studies, as well as translocation assays to ensure the strain does not enter the systemic circulation or cause adverse inflammatory responses.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
